期刊
LEUKEMIA & LYMPHOMA
卷 49, 期 4, 页码 659-662出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428190801888704
关键词
PET; lymphoma; interim; prognosis; ABVD; BEACOPP
Positron emission tomography using [18F]-fluoro-2-deoxy-D-glucose (FDG-PET) is an important tool for staging and treatment response assessment in malignant lymphomas. In Hodgkin lymphoma (HL), FDG-PET precisely predicts the therapy response when performed very early during standard ABVD chemotherapy. However, it is unclear whether FDG-PET retains this role if therapy is changed as a consequence of the scan, or if performed during a more intensive chemotherapy regimen such as BEACOPPesc, which is used for HL. This brief review presents the up-to-date evidence for the use and interpretation of early interim FDG-PET in HL, including recent preliminary results on early interim FDG-PET during BEACOPPesc therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据